Abstract

Autologous stem cell transplant (ASCT) remains an integral part of the treatment strategy for many myeloma patients. The role of allogeneic stem cell transplant continues to be defined. There is increasing evidence that posttransplant maintenance therapy can significantly improve outcomes. It is predicted that with more routine use of cytogenetic and gene expression profiling in the future, we will be better able to identify those subgroups of patients who are expected to benefit most from early versus late versus no ASCT and those who will benefit from allogeneic stem cell transplant.

Original languageEnglish (US)
Pages (from-to)1113-1129
Number of pages17
JournalHematology/Oncology Clinics of North America
Volume28
Issue number6
DOIs
StatePublished - Dec 1 2014

Fingerprint

Multiple Myeloma
Stem Cells
Transplants
Gene Expression Profiling
Cytogenetics
Therapeutics

Keywords

  • Immunomodulatory agents
  • Maintenance therapy
  • Proteasome inhibitors
  • Reduced-intensity conditioning

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Multiple myeloma. / Holstein, Sarah A.; Liu, Hong; McCarthy, Philip L.

In: Hematology/Oncology Clinics of North America, Vol. 28, No. 6, 01.12.2014, p. 1113-1129.

Research output: Contribution to journalReview article

Holstein, Sarah A. ; Liu, Hong ; McCarthy, Philip L. / Multiple myeloma. In: Hematology/Oncology Clinics of North America. 2014 ; Vol. 28, No. 6. pp. 1113-1129.
@article{0678729d0cd4463d8b434555b9e0f8a4,
title = "Multiple myeloma",
abstract = "Autologous stem cell transplant (ASCT) remains an integral part of the treatment strategy for many myeloma patients. The role of allogeneic stem cell transplant continues to be defined. There is increasing evidence that posttransplant maintenance therapy can significantly improve outcomes. It is predicted that with more routine use of cytogenetic and gene expression profiling in the future, we will be better able to identify those subgroups of patients who are expected to benefit most from early versus late versus no ASCT and those who will benefit from allogeneic stem cell transplant.",
keywords = "Immunomodulatory agents, Maintenance therapy, Proteasome inhibitors, Reduced-intensity conditioning",
author = "Holstein, {Sarah A.} and Hong Liu and McCarthy, {Philip L.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.hoc.2014.08.010",
language = "English (US)",
volume = "28",
pages = "1113--1129",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Multiple myeloma

AU - Holstein, Sarah A.

AU - Liu, Hong

AU - McCarthy, Philip L.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Autologous stem cell transplant (ASCT) remains an integral part of the treatment strategy for many myeloma patients. The role of allogeneic stem cell transplant continues to be defined. There is increasing evidence that posttransplant maintenance therapy can significantly improve outcomes. It is predicted that with more routine use of cytogenetic and gene expression profiling in the future, we will be better able to identify those subgroups of patients who are expected to benefit most from early versus late versus no ASCT and those who will benefit from allogeneic stem cell transplant.

AB - Autologous stem cell transplant (ASCT) remains an integral part of the treatment strategy for many myeloma patients. The role of allogeneic stem cell transplant continues to be defined. There is increasing evidence that posttransplant maintenance therapy can significantly improve outcomes. It is predicted that with more routine use of cytogenetic and gene expression profiling in the future, we will be better able to identify those subgroups of patients who are expected to benefit most from early versus late versus no ASCT and those who will benefit from allogeneic stem cell transplant.

KW - Immunomodulatory agents

KW - Maintenance therapy

KW - Proteasome inhibitors

KW - Reduced-intensity conditioning

UR - http://www.scopus.com/inward/record.url?scp=84912532689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912532689&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2014.08.010

DO - 10.1016/j.hoc.2014.08.010

M3 - Review article

C2 - 25459182

AN - SCOPUS:84912532689

VL - 28

SP - 1113

EP - 1129

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 6

ER -